Severe hypertriglyceridemia following sirolimus use in an infant
- 8 November 2021
- journal article
- research article
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (6) , 1581-1582
Abstract
Inhibitors of mammalian target of rapamycin function to downregulate cell growth and proliferation and have off‐label use in pediatrics for vascular malformations. Hypertriglyceridemia is a known side effect of mammalian target of rapamycin (mTOR) inhibitors. Further studies to better understand the incidence and treatment of hypertriglyceridemia in infants and neonates are warranted.Keywords
This publication has 5 references indexed in Scilit:
- Severe hypertriglyceridemia associated with everolimus drug-eluting stent placement in an infantCardiology in the Young, 2019
- Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angiomaPediatric Dermatology, 2018
- Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular AnomaliesPediatrics, 2016
- ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolismEuropean Journal of Endocrinology, 2014
- Sirolimus for the treatment of complicated vascular anomalies in childrenPediatric Blood & Cancer, 2011